A Phase 1 interventional study of ritlecitinib and ritlecitinib in Healthy Participants, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-21.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A phase I, single dose study to test two forms of pediatric ritlecitinib compared to adult ritlecitinib in healthy adults aged 18-55 years old. Approximately 12 adults will participate for approximately 2.5 months.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment sequence 1 will receive a single 30 milligrams (mg) ritlecitinib intact adult capsule during the first period, three 10 mg ritlecitinib pediatric capsules during the second period and 30 mg ritlecitinib spray congealed beads in the third period.
Drug: ritlecitinib
Treatment sequence 2 will receive three 10 mg ritlecitinib pediatric capsules during the first period, a single 30 mg intact adult capsule during the second period and 30 mg ritlecitinib spray congealed beads in the third period.
Drug: ritlecitinib
30 mg intact adult capsule
10 mg pediatric capsule
30 mg spray congealed beads
Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for Ritlecitinib
Plasma AUCinf for ritlecitinib is reported. AUCinf was calculated as \[AUClast+(Clast\*/kel)\], where AUClast is the area under the plasma concentration-time profile from time 0 to the time of the Clast, Clast is the last quantifiable concentration, Clast\* is the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, and 24 hours post dose on Day 1 in each period
Maximum Plasma Concentration (Cmax) for Ritlecitinib
Plasma Cmax for ritlecitinib is reported.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, and 24 hours post dose on Day 1 in each period
Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-Related)
An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Treatment-emergent AEs (TEAEs) = between first dose of study treatment and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-related AEs and SAEs were determined by the investigator. Severe=an event that prevents normal everyday activities.
Time frame: Post first dose of study intervention on Period 1 Day 1 up to 35 days post last dose of study intervention on Period 3 Day 1 (maximum of 40 days)
Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality
Following parameters were analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes, etc), chemistry (fasting glucose, calcium, sodium, potassium, chloride, total bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, uric acid, total protein, albumin, etc), and urinalysis (glucose, protein, blood, ketones, nitrites, leukocyte esterase, etc). Baseline = the last pre-dose measurement before Period 1 Day 1 (ie, first dose of study intervention). Laboratory abnormalities meeting pre-defined criteria are reported for this outcome measure. ULN=upper limit of normal. LLN=lower limit of normal. HPF=high-powered field. mEq=milliequivalent. L=liter.
Time frame: Baseline up to Period 3 Day 2 (maximum of 7 days)
| Milestone | [Sequence 1] Ritlecitinib: Intact Adult Capsule=>Pediatric Capsules=>Spray Congealed Beads | [Sequence 2] Ritlecitinib: Pediatric Capsules=>Intact Adult Capsule=>Spray Congealed Beads |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
| Milestone | [Sequence 1] Ritlecitinib: Intact Adult Capsule=>Pediatric Capsules=>Spray Congealed Beads | [Sequence 2] Ritlecitinib: Pediatric Capsules=>Intact Adult Capsule=>Spray Congealed Beads |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
| Milestone | [Sequence 1] Ritlecitinib: Intact Adult Capsule=>Pediatric Capsules=>Spray Congealed Beads | [Sequence 2] Ritlecitinib: Pediatric Capsules=>Intact Adult Capsule=>Spray Congealed Beads |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
Plasma AUCinf for ritlecitinib is reported. AUCinf was calculated as \[AUClast+(Clast\*/kel)\], where AUClast is the area under the plasma concentration-time profile from time 0 to the time of the Clast, Clast is the last quantifiable concentration, Clast\* is the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
| nanograms*hours/milliliter (ng*hr/mL) | Treatment A: Ritlecitinib 30 mg Intact Adult Capsule | Treatment B: Ritlecitinib 3*10 mg Pediatric Capsules | Treatment C: Ritlecitinib 30 mg Spray Congealed Beads |
|---|---|---|---|
| Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for Ritlecitinib | 361.1 ± 39 | 370.1 ± 40 | 385.1 ± 38 |
Plasma Cmax for ritlecitinib is reported.
| ng/mL | Treatment A: Ritlecitinib 30 mg Intact Adult Capsule | Treatment B: Ritlecitinib 3*10 mg Pediatric Capsules | Treatment C: Ritlecitinib 30 mg Spray Congealed Beads |
|---|---|---|---|
| Maximum Plasma Concentration (Cmax) for Ritlecitinib | 197.4 ± 38 | 199.6 ± 37 | 177.9 ± 30 |
An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Treatment-emergent AEs (TEAEs) = between first dose of study treatment and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-related AEs and SAEs were determined by the investigator. Severe=an event that prevents normal everyday activities.
| Participants | Treatment A: Ritlecitinib 30 mg Intact Adult Capsule | Treatment B: Ritlecitinib 3*10 mg Pediatric Capsules | Treatment C: Ritlecitinib 30 mg Spray Congealed Beads |
|---|---|---|---|
| Participants with AEs (All Causalities) | 2 | 1 | 1 |
| Participants with AEs (Treatment Related) | 0 | 0 | 0 |
| Participants with SAEs | 0 | 0 | 0 |
| Participants with Severe AEs | 0 | 0 | 0 |
Following parameters were analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes, etc), chemistry (fasting glucose, calcium, sodium, potassium, chloride, total bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, uric acid, total protein, albumin, etc), and urinalysis (glucose, protein, blood, ketones, nitrites, leukocyte esterase, etc). Baseline = the last pre-dose measurement before Period 1 Day 1 (ie, first dose of study intervention). Laboratory abnormalities meeting pre-defined criteria are reported for this outcome measure. ULN=upper limit of normal. LLN=lower limit of normal. HPF=high-powered field. mEq=milliequivalent. L=liter.
| Participants | Entire Study Population |
|---|---|
| Eosinophils/Leukocytes (%) >1.2*ULN | 1 |
| Monocytes/Leukocytes (%) >1.2*ULN | 2 |
| Bicarbonate (mEq/L) <0.9*LLN | 1 |
| Ketones (No Unit) >=1 | 1 |
| URINE Hemoglobin (No Unit) >=1 | 1 |
| Nitrite (No Unit) >=1 | 1 |
| Leukocyte Esterase (No Unit) >=1 | 1 |
| URINE Leukocytes (/HPF) >=20 | 1 |
| Bacteria (/HPF) >20 | 1 |
Collected over Baseline (ie, post the first dose of study intervention) up to 35 days post last dose of study intervention (maximum of 40 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A: Ritlecitinib 30 mg Intact Adult Capsule | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| Treatment B: Ritlecitinib 3*10 mg Pediatric Capsules | 0/12 (0%) | 0/12 (0%) | 1/12 (8.3%) |
| Treatment C: Ritlecitinib 30 mg Spray Congealed Beads | 0/12 (0%) | 0/12 (0%) | 1/12 (8.3%) |
| Event | Treatment A: Ritlecitinib 30 mg Intact Adult Capsule | Treatment B: Ritlecitinib 3*10 mg Pediatric Capsules | Treatment C: Ritlecitinib 30 mg Spray Congealed Beads |
|---|---|---|---|
| Vessel puncture site painGeneral disorders | 2/12 | 0/12 | 0/12 |
| FatigueGeneral disorders | 0/12 | 0/12 | 1/12 |
| HeadacheNervous system disorders | 0/12 | 1/12 | 0/12 |
| SomnolenceNervous system disorders | 0/12 | 1/12 | 0/12 |
Includes all participants assigned to study intervention and who took at least 1 dose of study intervention.
| Age, Continuous(Years) | Entire Study Population |
|---|---|
| Median | 40.0 (23 to 56) |
| Age, Customized(Participants) | Entire Study Population |
|---|---|
| 18-44 Years | 8 |
| 45-64 Years | 4 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 2 |
| Male | 10 |
| Race/Ethnicity, Customized(Participants) | Entire Study Population |
|---|---|
| White | 5 |
| Black or African American | 3 |
| Asian | 4 |
| Race/Ethnicity, Customized(Participants) | Entire Study Population |
|---|---|
| Hispanic or Latino | 3 |
| Not Hispanic or Latino | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Sep 2021 to primary completion in Nov 2021, 2 months.
Results were first posted in Aug 2023, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PF-06651600